Shalin Shah is a leader in metabolic health and a strong advocate for oral testosterone therapy as a key solution for men with testosterone deficiency. Passionate about holistic health and longevity, he focuses on advancing science-backed strategies to improve long-term well-being. As the CEO of Marius Pharmaceuticals, he drives the company’s strategy and operations across commercial and scientific functions. Since joining Marius in 2017 as Chief Financial Officer and EVP of Strategy, he has played a key role in advancing Phase 3 trials and strengthening the company’s IP portfolio. With 15 years of experience in the investment world—including operational roles at portfolio companies—Shalin brings a pragmatic approach that bridges business and healthcare. He began his career at Barclays London and is committed to reshaping healthcare through preventive strategies that address the global health crisis linked to declining testosterone levels.